CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
Mycophenolate Mofetil +1 moredrug
Likely dose
Mycophenolate Mofetil 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00910663
NCT00910663Phase 1Completed

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Mycophenolate Mofetil Capsules Under Fed Conditions

Teva Pharmaceuticals USA·interventional·Posted Jun 1, 2009·Updated Aug 19, 2024

In Brief

A Phase 1 clinical trial evaluating Mycophenolate Mofetil and CellCept® for Healthy. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The objective of this study was to compare the oral availability of a test product of Mycophenolate Mofetil 250 mg capsule to an equivalent oral dose of the commercially available reference product, CellCept® 250 mg capsule administered to healthy subjects under fed conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 1, 2009
Enrollment StartOct 1, 2006
Primary CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.1 years ago

Interventions

Mycophenolate Mofetildrug

250 mg Capsule

CellCept®drug

250 mg Capsule